# Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

> **NCT04069689** · PHASE1 · COMPLETED · sponsor: **Epygenix** · enrollment: 24 (actual)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** EPX-100 (Clemizole Hydrochloride)
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04069689
- **Lead sponsor:** Epygenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-29
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069689, "Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04069689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*